Symbiotec Pharmalab IPO Day 4: GMP at 29%, subscription reaches 5.31x — Should you subscribe?

Symbiotec Pharmalab IPO has entered its fourth and final day of bidding, with investors closely tracking subscription figures and grey market trends. The issue has continued to attract strong demand, while the grey market premium (GMP) stands at around Rs 285 per share, indicating a premium of nearly 29% over the upper end of the IPO price band.

The IPO has been subscribed 5.31 times overall against the 1.31 crore shares on offer. The retail portion has been subscribed 5.05 times, against 65.44 lakh shares reserved for retail investors.

Symbiotec Pharmalab is looking to raise Rs 1,757 crore through the IPO. The issue comprises a fresh issue of 15 lakh shares worth Rs 150 crore and an offer for sale (OFS) of 1.63 crore shares amounting to Rs 1,607 crore.


The company has fixed the IPO price band at Rs 938–Rs 988 per share.

The IPO opened on August 24 and will close on August 27, 2026. Investors can bid for a minimum of 15 shares and in multiples of 15 thereafter. At the upper price band, the minimum investment works out to Rs 14,820.

Symbiotec Pharmalab is set to list on both the BSE and NSE, with the tentative listing date scheduled for September 1, 2026. IPO allotment is expected to be finalised on August 28.

The issue is being managed by JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial, while MUFG Intime India Pvt. Ltd. is acting as the registrar.

IPO Anchor Investors : Symbiotec Pharmalab has raised Rs 526.20 crore from anchor investors ahead of its public issue. The anchor bidding for the IPO took place on August 21, 2026.

Symbiotec Pharmalab IPO Subscription Status

The Symbiotec Pharmalab IPO has entered its fourth and final day of bidding, with the issue continuing to witness strong investor demand. The IPO has been subscribed 5.31 times overall against the 1.31 crore shares available for subscription.

• Retail Individual Investors (RIIs): The retail portion has been subscribed 5.05 times, against 65.44 lakh shares reserved for retail investors.
• Non-Institutional Investors (NIIs): The NII portion has received 12.18 times subscription, compared with 28.04 lakh shares on offer.
• Qualified Institutional Buyers (QIBs): The QIB portion has been subscribed 59%, against 37.39 lakh shares reserved for institutional investors.

Symbiotec Pharmalab IPO GMP Today

The grey market premium (GMP) for the Symbiotec Pharmalab IPO is currently around Rs 285 per share, indicating a premium of nearly 29% over the upper end of the IPO price band of Rs 988.

If the current GMP remains unchanged, the IPO could potentially list at around Rs 1,273 per share, suggesting a potential gain of approximately 29% over the upper issue price.

However, GMP is an unofficial market indicator and can fluctuate before the stock makes its debut. Investors should therefore avoid relying solely on grey market trends and consider the company’s fundamentals, valuation and associated risks before making an investment decision.

Valuation

Symbiotec Pharmalab’s IPO valuation is likely to attract close attention from investors. Based on diluted earnings per share for fiscal 2026, the price-to-earnings (P/E) ratio stands at 49.37 times at the lower end of the price band and rises to 52.00 times at the upper end.

The company’s weighted average return on net worth for the last three financial years was 10.99%. With the IPO price band translating to 469 times the face value at the floor price and 494 times at the cap price, the issue is positioned as a premium offering in the pharmaceutical and biotechnology space.

Where Will the IPO Proceeds Go?

The Symbiotec Pharmalab IPO plans to channel Rs 112.50 crore towards the prepayment and/or repayment, fully or partially, of select outstanding borrowings, helping strengthen the company’s balance sheet and potentially reduce its debt burden.

The remaining proceeds will be allocated towards general corporate purposes, providing Symbiotec Pharmalab with greater financial flexibility to support its ongoing operations and future business needs.

About Symbiotec Pharmalab

Founded in 2002, Symbiotec Pharmalab operates across the biopharmaceutical and biotechnology space, developing and manufacturing active pharmaceutical ingredients (APIs), nutritional ingredients, and specialised products for domestic and international markets.

The company’s journey began with laboratory-scale manufacturing of steroidal-hormone APIs in 1995. Over the years, it has expanded into an industrial-scale, backward-integrated manufacturing platform serving the pharmaceutical, nutraceutical, and wellness sectors.

Research-driven manufacturing, quality and sustainability form key elements of its business strategy. Its manufacturing operations have also secured approvals and certifications from several international regulatory bodies, including the US FDA, EU-GMP authorities, and South Korea’s Ministry of Food and Drug Safety.

As of June 30, 2025, Symbiotec Pharmalab operated two industrial-scale API manufacturing plants. Together, these facilities had a maximum capacity of 584.67 metric tonnes (MT) for chemical synthesis and 300 kilolitres of fermentation capacity.

The combination of backward integration, specialised API capabilities, and international regulatory approvals gives the company an established position in a segment where manufacturing quality and regulatory compliance can be critical differentiators.

Should you subscribe to the Symbiotec Pharmalab IPO?

The IPO presents an interesting combination of strong grey-market sentiment, specialised manufacturing capabilities, and exposure to growing pharmaceutical markets.

According to a report by Master Capital Services Ltd.,"The global API market was valued at around USD 305.5 billion in 2025 and is expected to reach USD 424.6 billion by 2030, growing at a 6.8% CAGR. Small-molecule APIs continue to dominate, while biologics are gaining share. The CDMO market is also expected to grow strongly at an 8.2% CAGR, supported by India’s cost advantages and manufacturing capabilities."

The report further stated that Symbiotec Pharmalab provides exposure to specialised pharmaceutical manufacturing, with capabilities in corticosteroid and steroidal-hormone APIs, CDMO services and complex injectables. Its key strength is vertical integration across chemistry, biotechnology and regulated manufacturing. The IPO could offer a potential long-term investment opportunity, according to the report.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)